HK1219048A1 - Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl) - Google Patents
Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl)Info
- Publication number
- HK1219048A1 HK1219048A1 HK16107087.1A HK16107087A HK1219048A1 HK 1219048 A1 HK1219048 A1 HK 1219048A1 HK 16107087 A HK16107087 A HK 16107087A HK 1219048 A1 HK1219048 A1 HK 1219048A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pcsk9
- ldl
- kexin
- mudulate
- levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361765423P | 2013-02-15 | 2013-02-15 | |
US201361836381P | 2013-06-18 | 2013-06-18 | |
PCT/US2014/016640 WO2014127316A2 (en) | 2013-02-15 | 2014-02-15 | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1219048A1 true HK1219048A1 (en) | 2017-03-24 |
Family
ID=51354696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16107087.1A HK1219048A1 (en) | 2013-02-15 | 2016-06-20 | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2956154A4 (en) |
JP (1) | JP2016508722A (en) |
KR (1) | KR20150127622A (en) |
CN (1) | CN105378159A (en) |
AU (1) | AU2014216091A1 (en) |
CA (1) | CA2901436A1 (en) |
HK (1) | HK1219048A1 (en) |
IL (1) | IL240583A0 (en) |
SG (1) | SG11201506336XA (en) |
WO (1) | WO2014127316A2 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
LT2968443T (en) | 2013-03-15 | 2021-12-10 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
EP3960754A3 (en) | 2014-05-16 | 2022-07-06 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
RU2736637C9 (en) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases |
EP3182971A4 (en) | 2014-08-21 | 2018-04-25 | SRX Cardio, LLC | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
EP3200812B8 (en) | 2014-10-01 | 2021-04-28 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
MA41022A (en) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | LYSOSOMIAL TARGETING AND CORRESPONDING USES |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use |
US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
EP3337497B1 (en) | 2015-08-21 | 2023-07-12 | SRX Cardio, LLC | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
WO2017058113A1 (en) * | 2015-09-28 | 2017-04-06 | Agency For Science, Technology And Research | Coating for metal nanoparticles |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
CN109475593A (en) | 2016-06-24 | 2019-03-15 | 豪夫迈·罗氏有限公司 | For treating the composition and method of cardiovascular disease |
TW201823222A (en) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | Compound, pharmaceutical composition and use thereof |
TW201920234A (en) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | Opioid agonist peptides and uses thereof |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
CN113574055B (en) | 2019-01-18 | 2024-07-23 | 阿斯利康(瑞典)有限公司 | PCSK9 inhibitors and methods of use thereof |
EP3997105A4 (en) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2021146441A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CN115279782A (en) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
BR112023018676A2 (en) | 2021-03-18 | 2023-10-10 | Seagen Inc | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION, METHODS OF TREATMENT OF A DISEASE OR CONDITION AND A CANCER, AND, LINDER-DRUG CONJUGATE COMPOSITION |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
PT2483266E (en) * | 2009-10-01 | 2015-06-30 | Cadila Healthcare Ltd | Compounds for the treatment of dyslipidemia and related diseases |
CN102206249B (en) * | 2011-04-26 | 2013-07-03 | 中国农业科学院哈尔滨兽医研究所 | Specific B cell epitope polypeptide of NS1 protein of encephalitis B virus and use thereof |
-
2014
- 2014-02-15 KR KR1020157025152A patent/KR20150127622A/en not_active Application Discontinuation
- 2014-02-15 WO PCT/US2014/016640 patent/WO2014127316A2/en active Application Filing
- 2014-02-15 CA CA2901436A patent/CA2901436A1/en not_active Abandoned
- 2014-02-15 EP EP14751148.9A patent/EP2956154A4/en not_active Withdrawn
- 2014-02-15 AU AU2014216091A patent/AU2014216091A1/en not_active Abandoned
- 2014-02-15 CN CN201480017801.7A patent/CN105378159A/en active Pending
- 2014-02-15 SG SG11201506336XA patent/SG11201506336XA/en unknown
- 2014-02-15 JP JP2015558178A patent/JP2016508722A/en active Pending
-
2015
- 2015-08-13 IL IL240583A patent/IL240583A0/en unknown
-
2016
- 2016-06-20 HK HK16107087.1A patent/HK1219048A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2901436A1 (en) | 2014-08-21 |
IL240583A0 (en) | 2015-09-24 |
KR20150127622A (en) | 2015-11-17 |
AU2014216091A1 (en) | 2015-09-03 |
WO2014127316A3 (en) | 2014-10-09 |
SG11201506336XA (en) | 2015-09-29 |
WO2014127316A4 (en) | 2014-12-04 |
EP2956154A2 (en) | 2015-12-23 |
JP2016508722A (en) | 2016-03-24 |
WO2014127316A2 (en) | 2014-08-21 |
EP2956154A4 (en) | 2016-07-27 |
CN105378159A (en) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219048A1 (en) | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl) | |
HK1243075A1 (en) | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) | |
ZA201409210B (en) | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
HK1207592A1 (en) | Stable formulations containing anti-pcsk9 antibodies pcsk9 | |
HK1216841A1 (en) | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) 9(pcsk9) | |
IL266066A (en) | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction | |
IL293355B2 (en) | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder | |
EP2968266A4 (en) | Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | |
HK1202804A1 (en) | Treatment with anti-pcsk9 antibodies pcsk9 | |
IL231011A0 (en) | Methods for reducing lipoprotein(a)levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) | |
MX2016006226A (en) | Dosing regimens for use with pcsk9 inhibitors. | |
ZA201307499B (en) | Compositions and methods comprising serine protease variants | |
DK3666797T3 (en) | ANTIGEN-BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | |
IL240437A0 (en) | Serum fraction of platelet-rich fibrin | |
HK1213194A1 (en) | Novel binding proteins for pcsk9 pcsk9 | |
MX2015016887A (en) | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9. | |
EP3182971A4 (en) | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity | |
HK1257102A1 (en) | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use | |
SG11201510523QA (en) | Pump housing made of a magnetic and a non-magnetic material | |
MX2017011879A (en) | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders. | |
EP2771358A4 (en) | Removal of virucidal agents in mixed mode chromatography | |
EP2682123A4 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
GB201306127D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) | |
HK1218140A1 (en) | Milk clotting aspartic protease enzyme composition | |
GB201602153D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) |